Atomwise and Sanofi partner for drug discovery using AI
Atomwise is entitled to receive research, development and sales-based milestone payments totalling over $1bn.
Deal News
Latest in
Deal News
AGC and RoosterBio partner for cell and exosome therapy manufacturing
RoosterBio will use its cell and media product portfolio to create scalable processes for hMSC and exosome therapies.
Merck and Orna partner for RNA technology-based vaccines and therapies
Orna is entitled to receive development, regulatory and sales-based milestone payments totalling up to $3.5bn.
Q32 Bio and Horizon partner to develop autoimmune disease treatment
Q32 is entitled to get $55m as initial consideration and staged development funding during the option period.
Gilead to acquire global rights of Trodelvy from Everest
Under the deal, Gilead has a chance to hire Everest staff working on the Trodelvy programme.
Ceapro and McMaster extend partnership to develop Covid-19 therapy
This assessment in experimental models of lung fibrosis will aid in progressing the technology into a Phase I clinical trial.
GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
Gemini enters business combination deal with Disc Medicine
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.